Quest Diagnostics Inc. DGX, -0.16% said Thursday its second-quarter net income fell to $234 million, or $1.96 a share from $631 million, or $4.96 a share in the year-ago quarter. Adjusted profit in the latest quarter totaled $2.36 a share. Second-quarter net revenue fell 3.8% to $2.45 billion from $2.55 billion in the year-ago quarter. Wall Street analysts expected Quest Diagnostics to earn $2.29 a share on revenue of $2.34 billion, according to a survey by data provider FactSet. The company’s COVID-19 testing revenue fell to $344 million from $511 million a year ago. Looking ahead, Quest Diagnostic now expects adjusted 2022 earnings of $9.55 to $9.95 a share, ahead of the analyst estimate of $9.33 a share. The company hiked its outlook from $9 to $9.50 a share. Shares of Quest Diagnostics have dropped 22.1% in 2022, compared to a loss of 16.9% by the S&P 500.